Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Ascendis Pharma A (ASND) Non-Current Receivables (2019 - 2025)

Ascendis Pharma A's Non-Current Receivables history spans 4 years, with the latest figure at $2.3 million for Q4 2023.

  • For Q4 2023, Non-Current Receivables changed N/A year-over-year to $2.3 million; the TTM value through Dec 2023 reached $2.3 million, changed N/A, while the annual FY2023 figure was $2.3 million, N/A changed from the prior year.
  • Non-Current Receivables for Q4 2023 was $2.3 million at Ascendis Pharma A, up from $2.1 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $2.3 million in Q4 2023 and bottomed at $1.6 million in Q4 2019.
  • The 4-year median for Non-Current Receivables is $1.9 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Non-Current Receivables grew 1.24% in 2020 before it grew 26.16% in 2021.
  • A 4-year view of Non-Current Receivables shows it stood at $1.6 million in 2019, then grew by 1.24% to $1.6 million in 2020, then grew by 26.16% to $2.1 million in 2021, then grew by 10.65% to $2.3 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Non-Current Receivables are $2.3 million (Q4 2023), $2.1 million (Q4 2021), and $1.6 million (Q4 2020).